Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Monotherapy in Pre-treated Metastatic Breast Cancer
NCT00191269Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2005
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Tumor Response. Started Jun 2005; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00191269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191269.